12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Company News  |  Deals

NPS, GlaxoSmithKline deal

NPS and GlaxoSmithKline terminated a 1993 deal to develop and commercialize compounds to treat osteoporosis and replaced it with a new deal under which GSK assigned all rights to an undisclosed number of compounds, including INDs for SB-423557 ( NPSP790) and SB-423562 ( NPSP795). Both compounds...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >